{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:03:42Z","timestamp":1780567422756,"version":"3.54.1"},"reference-count":96,"publisher":"European Respiratory Society (ERS)","issue":"178","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2025,9,9]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:p>\n                    A large proportion of patients (40\u201360%) with severe asthma present with persistent airway obstruction (PAO). Patients with severe eosinophilic asthma (SEA) and PAO appear to be an underrepresented group in clinical guidance, despite being associated with considerable healthcare and economic burden. High levels of eosinophils drive airway inflammation, obstruction and hyperresponsiveness, which are key characteristics of SEA and can increase the risk of PAO and subsequent irreversible worsening of lung function. Available clinical and real-world data must examine the effectiveness of biologic treatment targeting SEA in PAO to identify any data gaps that might help further define such patients and optimise their management. However, clinical trials of SEA frequently exclude the enrolment of patients with PAO. Eosinophils are activated and recruited to airways in response to different cytokines, particularly interleukin-5 (IL-5), produced\n                    <jats:italic>via<\/jats:italic>\n                    a complex molecular and cellular cascade. A few studies evaluating the effectiveness of benralizumab and mepolizumab were able to identify cohorts of patients with SEA and PAO who had a significant response to these IL-5\/R\u03b1-targeted biologics. PAO in patients with SEA represents a distinct clinical entity, one which could be referred to as \u201cpersistent eosinophilic airway obstruction\u201d. Patients with persistent eosinophilic airway obstruction are likely to be responsive to targeted biologic treatment, although additional clinical studies and real-world data are needed to further assess treatment efficacy and safety in this population and provide guidance to clinical practice.\n                  <\/jats:p>","DOI":"10.1183\/16000617.0024-2025","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T09:30:12Z","timestamp":1765359012000},"page":"250024","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Persistent airway obstruction in severe eosinophilic asthma: targeting interleukin-5 and eosinophils"],"prefix":"10.1183","volume":"34","author":[{"given":"Nicola A.","family":"Hanania","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7638-2506","authenticated-orcid":false,"given":"Felix J.F.","family":"Herth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"2025121001300526000_34.178.250024.1","unstructured":"Global Initiative for Asthma . Global strategy for asthma management and prevention. Date last updated: 2024. Date last accessed: May 2024. https:\/\/ginasthma.org\/2024-report\/"},{"key":"2025121001300526000_34.178.250024.2","unstructured":"Global Initiative for Asthma . Difficult-to-treat and severe asthma in adolescent and adult patients. Date last updated: 2023. Date last accessed: 26 February 2024. https:\/\/ginasthma.org\/wp-content\/uploads\/2024\/11\/GINA-Severe-Asthma-Guide-2024-WEB-WMS.pdf"},{"key":"2025121001300526000_34.178.250024.3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.18176\/jiaci.0871","article-title":"Prevalence, T2 biomarkers, and cost of severe asthma in the era of biologics: the BRAVO-1 study","volume":"34","author":"Domingo","year":"2024","journal-title":"J Investig Allergol Clin Immunol"},{"key":"2025121001300526000_34.178.250024.4","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.chest.2021.04.013","article-title":"Eosinophilic and noneosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort","volume":"160","author":"Heaney","year":"2021","journal-title":"Chest"},{"key":"2025121001300526000_34.178.250024.5","first-page":"825","article-title":"Incremental cost burden among patients with severe uncontrolled asthma in the United States","volume":"29","author":"Burnette","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"key":"2025121001300526000_34.178.250024.6","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2017-210531"},{"key":"2025121001300526000_34.178.250024.7","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12890-016-0263-8","article-title":"Burden of asthma with elevated blood eosinophil levels","volume":"16","author":"Casciano","year":"2016","journal-title":"BMC Pulm Med"},{"key":"2025121001300526000_34.178.250024.8","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.anai.2020.04.024","article-title":"Effect of clinically significant thresholds of eosinophil elevation on health care resource use in asthma","volume":"125","author":"Dotiwala","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2025121001300526000_34.178.250024.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2019.08.462"},{"key":"2025121001300526000_34.178.250024.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199810223391703"},{"key":"2025121001300526000_34.178.250024.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.06.035"},{"key":"2025121001300526000_34.178.250024.12","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00162414"},{"key":"2025121001300526000_34.178.250024.13","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12931-017-0559-0","article-title":"Clinical characteristics of eosinophilic COPD versus COPD patients with a history of asthma","volume":"18","author":"Kolsum","year":"2017","journal-title":"Respir Res"},{"key":"2025121001300526000_34.178.250024.14","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.3390\/cells12121631","article-title":"Blood and sputum eosinophils of COPD patients are differently polarized than in asthma","volume":"12","author":"Mycroft","year":"2023","journal-title":"Cells"},{"key":"2025121001300526000_34.178.250024.15","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.2147\/COPD.S54927","article-title":"Airflow obstruction: is it asthma or is it COPD?","volume":"11","author":"Rogliani","year":"2016","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2025121001300526000_34.178.250024.16","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-019-1198-4"},{"key":"2025121001300526000_34.178.250024.17","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S312560"},{"key":"2025121001300526000_34.178.250024.18","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0185-2019"},{"key":"2025121001300526000_34.178.250024.19","doi-asserted-by":"crossref","first-page":"271","DOI":"10.5603\/ARM.a2017.0045","article-title":"Eosinophilic COPD \u2013 a distinct phenotype of the disease","volume":"85","author":"Tworek","year":"2017","journal-title":"Adv Respir Med"},{"key":"2025121001300526000_34.178.250024.20","doi-asserted-by":"crossref","first-page":"2317356","DOI":"10.1080\/07853890.2024.2317356","article-title":"Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma: a long-term retrospective analysis","volume":"56","author":"Basagana","year":"2024","journal-title":"Ann Med"},{"key":"2025121001300526000_34.178.250024.21","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3390\/jpm13071173","article-title":"Characterization and factors associated with poor asthma control in adults with severe eosinophilic asthma","volume":"13","author":"Padr\u00f3-Casas","year":"2023","journal-title":"J Pers Med"},{"key":"2025121001300526000_34.178.250024.22","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00108514"},{"key":"2025121001300526000_34.178.250024.23","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jaci.2024.10.024","article-title":"Effect of mepolizumab in airway remodeling in patients with late-onset severe asthma with an eosinophilic phenotype","volume":"155","author":"Domvri","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"2025121001300526000_34.178.250024.24","doi-asserted-by":"crossref","first-page":"100078","DOI":"10.1016\/j.waojou.2019.100078","article-title":"Distinct profile of inflammatory and remodelling biomarkers in sputum of severe asthmatic patients with or without persistent airway obstruction","volume":"12","author":"Cianchetti","year":"2019","journal-title":"World Allergy Organ J"},{"key":"2025121001300526000_34.178.250024.25","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3109\/02770903.2016.1155220","article-title":"Irreversible airway obstruction in asthma: a risk factor for severe exacerbations in spite of proper treatment","volume":"53","author":"Muniz","year":"2016","journal-title":"J Asthma"},{"key":"2025121001300526000_34.178.250024.26","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/cea.13302","article-title":"Fixed airflow obstruction relates to eosinophil activation in asthmatics","volume":"49","author":"Mogensen","year":"2019","journal-title":"Clin Exp Allergy"},{"key":"2025121001300526000_34.178.250024.27","doi-asserted-by":"publisher","DOI":"10.1378\/chest.07-0713"},{"key":"2025121001300526000_34.178.250024.28","doi-asserted-by":"crossref","first-page":"106202","DOI":"10.1016\/j.rmed.2020.106202","article-title":"Clinical and biological factors associated with irreversible airway obstruction in adult asthma","volume":"175","author":"Graff","year":"2020","journal-title":"Respir Med"},{"key":"2025121001300526000_34.178.250024.29","first-page":"5403","article-title":"Risk factors related to persistent airflow obstruction in severe asthma in Chinese Han population","volume":"7","author":"Zhang","year":"2014","journal-title":"Int J Clin Exp Med"},{"key":"2025121001300526000_34.178.250024.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2015.09.009"},{"key":"2025121001300526000_34.178.250024.31","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.164.5.2011026"},{"key":"2025121001300526000_34.178.250024.32","first-page":"165","article-title":"Treatable traits in misdiagnosed chronic obstructive pulmonary disease: data from the Akershus cardiac examination 1950 study","volume":"9","author":"Caspersen","year":"2022","journal-title":"Chronic Obstr Pulm Dis"},{"key":"2025121001300526000_34.178.250024.33","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3109\/02770903.2014.895012","article-title":"Fixed airflow obstruction in asthma: a descriptive study of patient profiles and effect on treatment responses","volume":"51","author":"Tashkin","year":"2014","journal-title":"J Asthma"},{"key":"2025121001300526000_34.178.250024.34","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.58.4.322"},{"key":"2025121001300526000_34.178.250024.35","first-page":"9868704","article-title":"Risk factors associated with irreversible airway obstruction in asthma: a systematic review and meta-analysis","volume":"2016","author":"Zhang","year":"2016","journal-title":"Biomed Res Int"},{"key":"2025121001300526000_34.178.250024.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.01.003"},{"key":"2025121001300526000_34.178.250024.37","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S2213-2600(22)00185-0","article-title":"Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study","volume":"11","author":"Kole","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2025121001300526000_34.178.250024.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2017.10.004"},{"key":"2025121001300526000_34.178.250024.39","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.04.00077803"},{"key":"2025121001300526000_34.178.250024.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2008.04.011"},{"key":"2025121001300526000_34.178.250024.41","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2500\/aap.2014.35.3785","article-title":"Risk factors associated with irreversible airway obstruction in nonsmoking adult patients with severe asthma","volume":"35","author":"Ciebiada","year":"2014","journal-title":"Allergy Asthma Proc"},{"key":"2025121001300526000_34.178.250024.42","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.898208"},{"key":"2025121001300526000_34.178.250024.43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2032506"},{"key":"2025121001300526000_34.178.250024.44","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2019.01514"},{"key":"2025121001300526000_34.178.250024.45","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.anai.2019.10.006","article-title":"Benralizumab efficacy for patients with fixed airflow obstruction and severe, uncontrolled eosinophilic asthma","volume":"124","author":"Chipps","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2025121001300526000_34.178.250024.46","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.rmed.2019.04.020","article-title":"Increase in blood eosinophils during follow-up is associated with lung function decline in adult asthma","volume":"152","author":"Graff","year":"2019","journal-title":"Respir Med"},{"key":"2025121001300526000_34.178.250024.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.04.005"},{"key":"2025121001300526000_34.178.250024.48","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jaip.2021.09.023","article-title":"Anti-interleukin-5 therapy is associated with attenuated lung function decline in severe eosinophilic asthma patients from the Belgian severe asthma registry","volume":"10","author":"Graff","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025121001300526000_34.178.250024.49","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2500\/aap.2016.37.3991","article-title":"Effects of the addition of tiotropium on airway dimensions in symptomatic asthma","volume":"37","author":"Hoshino","year":"2016","journal-title":"Allergy Asthma Proc"},{"key":"2025121001300526000_34.178.250024.50","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0150-2021"},{"key":"2025121001300526000_34.178.250024.51","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathmechdis-012419-032756"},{"key":"2025121001300526000_34.178.250024.52","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1939-4551-7-32","article-title":"Anti-IL5 therapy for asthma and beyond","volume":"7","author":"Mukherjee","year":"2014","journal-title":"World Allergy Organ J"},{"key":"2025121001300526000_34.178.250024.53","doi-asserted-by":"crossref","first-page":"9095275","DOI":"10.1155\/2018\/9095275","article-title":"Eosinophils from physiology to disease: a comprehensive review","volume":"2018","author":"Ramirez","year":"2018","journal-title":"Biomed Res Int"},{"key":"2025121001300526000_34.178.250024.54","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12948-021-00146-9","article-title":"Defining type 2 asthma and patients eligible for dupilumab in Italy: a biomarker-based analysis","volume":"19","author":"Canonica","year":"2021","journal-title":"Clin Mol Allergy"},{"key":"2025121001300526000_34.178.250024.55","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.3390\/cells11071105","article-title":"The role of airway epithelial cell alarmins in asthma","volume":"11","author":"Whetstone","year":"2022","journal-title":"Cells"},{"key":"2025121001300526000_34.178.250024.56","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1172\/JCI124606","article-title":"Epithelial cell-derived cytokines: more than just signaling the alarm","volume":"129","author":"Roan","year":"2019","journal-title":"J Clin Invest"},{"key":"2025121001300526000_34.178.250024.57","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/all.15609","article-title":"Sounding the alarmins\u2013the role of alarmin cytokines in asthma","volume":"78","author":"Gauvreau","year":"2023","journal-title":"Allergy"},{"key":"2025121001300526000_34.178.250024.58","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0902515"},{"key":"2025121001300526000_34.178.250024.59","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00301.2005"},{"key":"2025121001300526000_34.178.250024.60","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3389\/fmed.2017.00093","article-title":"The biology of eosinophils and their role in asthma","volume":"4","author":"McBrien","year":"2017","journal-title":"Front Med"},{"key":"2025121001300526000_34.178.250024.61","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1608969"},{"key":"2025121001300526000_34.178.250024.62","doi-asserted-by":"publisher","DOI":"10.1172\/JCI95693"},{"key":"2025121001300526000_34.178.250024.63","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202110-2265OC"},{"key":"2025121001300526000_34.178.250024.64","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jaip.2022.09.008","article-title":"Clinical associations of mucus plugging in moderate to severe asthma","volume":"11","author":"Chan","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025121001300526000_34.178.250024.65","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01359-2015"},{"key":"2025121001300526000_34.178.250024.66","unstructured":"US Food and Drug Administration . FASENRA (benralizumab) prescribing information. Date last accessed: 22 February 2024. Date last updated: 2017. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761070s000lbl.pdf"},{"key":"2025121001300526000_34.178.250024.67","unstructured":"European Medicines Agency . FASENRA (benralizumab) summary of product characteristics. Date last accessed: February 2025. Date last updated: 13 February 2024. www.ema.europa.eu\/en\/documents\/product-information\/fasenra-epar-product-information_en.pdf"},{"key":"2025121001300526000_34.178.250024.68","unstructured":"US Food and Drug Administration . NUCALA (meoplizumab) prescribing information. Date last accessed: 22 February 2024. Date last updated: February 2017. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125526s002lbl.pdf"},{"key":"2025121001300526000_34.178.250024.69","unstructured":"European Medicines Agency . NUCALA (meoplizumab) summary of product characteristics. Date last accessed: 13 June 2025. Date last updated: 11 May 2022. www.ema.europa.eu\/en\/documents\/product-information\/nucala-epar-product-information_en.pdf"},{"key":"2025121001300526000_34.178.250024.70","unstructured":"US Food and Drug Administration . CINQAIR (reslizumab) prescribing information. Date last accessed: 11 December 2024. Date last updated: March 2016. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/761033lbl.pdf"},{"key":"2025121001300526000_34.178.250024.71","unstructured":"European Medicines Agency . CINQAERO (reslizumab) summary of product characteristics. Date last accessed: 11 December 2024. Date last updated: 2018. www.ema.europa.eu\/en\/documents\/product-information\/cinqaero-epar-product-information_en.pdf"},{"key":"2025121001300526000_34.178.250024.72","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31324-1"},{"key":"2025121001300526000_34.178.250024.73","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.04.004"},{"key":"2025121001300526000_34.178.250024.74","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.05.020"},{"key":"2025121001300526000_34.178.250024.75","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.04.005"},{"key":"2025121001300526000_34.178.250024.76","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31322-8"},{"key":"2025121001300526000_34.178.250024.77","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2016.01.003"},{"key":"2025121001300526000_34.178.250024.78","first-page":"CD010834","article-title":"Anti-IL-5 therapies for asthma","volume":"7","author":"Farne","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121001300526000_34.178.250024.79","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00586-2022"},{"key":"2025121001300526000_34.178.250024.80","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.2147\/COPD.S468887","article-title":"Real-world effectiveness of benralizumab among patients with asthma and concomitant chronic obstructive pulmonary disease","volume":"19","author":"Carstens","year":"2024","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2025121001300526000_34.178.250024.81","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2021.05.021"},{"key":"2025121001300526000_34.178.250024.82","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1016\/j.jaip.2023.07.024","article-title":"Mepolizumab in patients with severe asthma and comorbidities: 1-year REALITI-A analysis","volume":"11","author":"Liu","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025121001300526000_34.178.250024.83","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1159\/000534922","article-title":"Response to various biologics in patients with both asthma and chronic obstructive pulmonary disease","volume":"102","author":"Lommatzsch","year":"2023","journal-title":"Respiration"},{"key":"2025121001300526000_34.178.250024.84","doi-asserted-by":"crossref","first-page":"100848","DOI":"10.1016\/j.waojou.2023.100848","article-title":"A comparison of treatment response to biologics in asthma\u2013COPD overlap and pure asthma: findings from the PRISM study","volume":"16","author":"Shim","year":"2023","journal-title":"World Allergy Organ J"},{"key":"2025121001300526000_34.178.250024.85","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403290"},{"key":"2025121001300526000_34.178.250024.86","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60988-X"},{"key":"2025121001300526000_34.178.250024.87","first-page":"A4683","article-title":"Effect of mepolizumab on exacerbations in asthma patients with features common in COPD","volume":"195","author":"Yancy","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2025121001300526000_34.178.250024.88","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.congress-2023.OA3152"},{"key":"2025121001300526000_34.178.250024.89","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.congress-2024.PA5366"},{"key":"2025121001300526000_34.178.250024.90","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.2169\/internalmedicine.3531-24","article-title":"Usefulness of mepolizumab for mucus plugs","volume":"63","author":"Hamakawa","year":"2024","journal-title":"Intern Med"},{"key":"2025121001300526000_34.178.250024.91","doi-asserted-by":"publisher","DOI":"10.1159\/000530392"},{"key":"2025121001300526000_34.178.250024.92","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.chest.2023.02.009","article-title":"CT mucus score and 129Xe MRI ventilation defects after 2.5 years\u2019 anti-IL-5R\u03b1 in eosinophilic asthma","volume":"164","author":"McIntosh","year":"2023","journal-title":"Chest"},{"key":"2025121001300526000_34.178.250024.93","doi-asserted-by":"crossref","first-page":"107611","DOI":"10.1016\/j.rmed.2024.107611","article-title":"Benralizumab efficacy and safety in severe asthma: a randomized trial in Asia","volume":"229","author":"Lai","year":"2024","journal-title":"Respir Med"},{"key":"2025121001300526000_34.178.250024.94","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1513\/AnnalsATS.202406-597OC","article-title":"Role of monoclonal antibodies in the management of eosinophilic chronic obstructive pulmonary disease: a meta-analysis of randomized controlled trials","volume":"22","author":"Mohamed","year":"2025","journal-title":"Ann Am Thorac Soc"},{"key":"2025121001300526000_34.178.250024.95","doi-asserted-by":"crossref","first-page":"2449889","DOI":"10.1080\/15412555.2025.2449889","article-title":"Biologic therapies for chronic obstructive pulmonary disease: a systematic review and network meta-analysis of randomized controlled trials","volume":"22","author":"Pitre","year":"2025","journal-title":"COPD"},{"key":"2025121001300526000_34.178.250024.96","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413181"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0024-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T09:30:49Z","timestamp":1765359049000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0024-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":96,"journal-issue":{"issue":"178","published-online":{"date-parts":[[2025,12,10]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1183\/16000617.0024-2025"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0024-2025","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}